Poland· PL-100541919
Cenrifki
A tolebrutinib product containing tolebrutinib, registered in Poland by Sanofi Winthrop Industrie. The same ATC class is registered in 5 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Tolebrutinib is registered in 5 of 19 countries.
Countries holding a registration under ATC L04AA62 (tolebrutinib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 4 of them publish a price we can compare per daily dose
Tolebrutinib · ATC L04AA62
5 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Netherlands
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Tolebrutinib
- Manufacturer
- Sanofi Winthrop Industrie
- Country
- Poland (PL)
- ATC code
- L04AA62
- ATC class
- Tolebrutinib
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909991605629
- gtin05909991605636
- gtin05909991605643
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tolebrutinib in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCENRIFKISanofi Winthrop Industrie, Gentilly
- SpainCENRIFKI 60 MG COMPRIMIDOS RECUBIERTOS CON PELICULASanofi Winthrop Industrie
- BelgiumCenrifki 60 mgSanofi Winthrop Industrie
- IrelandCenrifki 60 mg film-coated tabletsSanofi Winthrop Industrie
- NetherlandsCenrifki 60 mg filmomhulde tablettenSanofi Winthrop Industrie
- SwedenCenrifki 60 mg Filmdragerad tablettSanofi Winthrop Industrie
- FinlandCenrifkiSanofi Winthrop Industrie
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cenrifki
- Liechtenstein · Cenrifki
- Norway · Cenrifki
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/279a342b-7ec1-4893-82f2-1ca77d97e39a GET /v1/drugs/279a342b-7ec1-4893-82f2-1ca77d97e39a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "60 mg",
"packaging": "05909991605629 ¦ Rpz ¦ EU/1/25/2011/001 ¦ 167789\n7 tabl.\n05909991605636 ¦ Rpz ¦ EU/1/25/2011/002 ¦ 167790\n28 tabl.\n05909991605643 ¦ Rpz ¦ EU/1/25/2011/003 ¦ 167791\n98 tabl.",
"substance": "Tolebrutinib/60 mg",
"common_name": "Tolebrutinib",
"pl_product_id": "100541919",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about tolebrutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.